Cardiovascular Revascularization Medicine
Volume 8, Issue 4 , Pages 230-235 , October 2007

First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study

  • Nicholas Kipshidze

      Affiliations

    • Lenox Hill Heart and Vascular Institute, New York, NY
    • Corresponding Author InformationCorresponding author. Lenox Hill Heart and Vascular Institute, 130 East 77th Street, Black Hall, 9th Floor, New York, NY 10021, USA. Tel.: +1 212 434-6835; fax: +1 212 434-2205.
    • ,
  • Patrick Iversen

      Affiliations

    • AVI BioPharma, Portland, OR, USA
    • ,
  • Paul Overlie

      Affiliations

    • Covenant Hospital, Lubbock, TX, USA
    • ,
  • Tom Dunlap

      Affiliations

    • Santa Rosa Memorial Hospital, Santa Rosa, CA, USA
    • ,
  • Bradley Titus

      Affiliations

    • Legacy Good Samaritan Hospital, Portland, OR, USA
    • ,
  • Don Lee

      Affiliations

    • Glendale Memorial Hospital Glendale, CA, USA
    • ,
  • Jeffrey Moses

      Affiliations

    • Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA
    • ,
  • Peter O'Hanley

      Affiliations

    • School of Public Health and Medicine, George Washington University, Washington, DC, USA
    • ,
  • Michael Lauer

      Affiliations

    • Borgess Medical Center, Kalamazoo, MI, USA
    • ,
  • Martin B. Leon

      Affiliations

    • Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA

Received 7 February 2007 ,Revised 11 April 2007 ,Accepted 11 April 2007.

References 

  1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780
  2. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108(7):788–794
  3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  4. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215–1223
  5. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001;86:262–264
  6. Kuchulakanti PK, William W, Chu WW, Rebecca Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113(8):1108–1113
  7. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112(2):270–278
  8. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701–1706
  9. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting stents after discontinuation of platelet therapy. Lancet. 2004;364:1519–1521
  10. Nebeker JR, Virmani R, Charles L, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175–181
  11. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231–236
  12. Hofma SH, van der Giessen WJ, van Dalen BM. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur J Heart. 2006;27(2):166–170[Electronic publication 2005 Oct 25]
  13. Kipshidze NN, Kim HS, Iversen P, et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol. 2002;39(10):1686–1691
  14. Kipshidze N, Keane D, Stein D. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardvasc Interv. 2001;54(2):247–256
  15. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv. 2004;61(4):518–527
  16. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 1997;7:63–70
  17. Taylor MF, Paulaskis JD, Weller DD, et al. In vivo efficacy of morpholino modified oligomers directed against tumor necrosis factor-a mRNA. J Biol Chem. 1996;29:17452–17455
  18. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 1992;86:538–547
  19. Simons M, Edelman ER, DeKeyser JL, et al. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67–70
  20. Gunn J, Holt CM, Francis SE, et al. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res. 1997;80:520–531
  21. Zalewski A, Shi Y, Mannion JD, et al. In:  Wickstrom E editors. Synthetic DNA-Based compounds for the prevention of coronary restenosis: current status and future challenges in clinical trials of genetic therapy with antisense DNA and DNA vectors. New York, NY: Marcell Dekker; 1998;p. 363–393
  22. Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996;6:267–272
  23. Hudziak RM, Summerton J, Weller DD, et al. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. 2000;10:163–176
  24. Arora V, Knapp DC, Smith BL, et al. c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A Activity. J Pharmacol Exp Ther. 2000;292:921–928
  25. Kipshidze N, Iversen P, Keane E, et al. Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc Radiat Med. 2002;3:26–30
  26. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized Investigation by the Thoraxcenter of Antisense DNA Using Local Delivery and IVUS After Coronary Stenting (ITALICS) trial. J Am Coll Cardiol. 2002;39(2):281–287

PII: S1553-8389(07)00135-2

doi: 10.1016/j.carrev.2007.04.002

Cardiovascular Revascularization Medicine
Volume 8, Issue 4 , Pages 230-235 , October 2007

Article Tools

* Image Usage & Resolution